Blood Screening Market to Showcase Lucrative Growth Opportunities During 2016-21

The ****** Blood Screening Market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%.

Factors such as increasing number of blood donations and blood donors, growing affordability and adoption of nucleic acid test (NAT) for blood screening, rising awareness regarding the safety of donated blood, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases are driving the growth of the Blood Screening Market.

Download PDF Brochure:

Blood Screening Market segmentation:

  • based on product
  • based on technology
  • based on end users,
  • based on regions.

The key strategies followed by most companies in the Blood Screening Market are product launches, approvals, agreements, acquisition, and expansion. The product launches strategy accounted for the largest share of the overall growth strategies mapped from 2013 to 2016. Some of the leading players that adopted this strategy include Roche Diagnostics, Abbott Laboratories, bioMérieux, and Bio-Rad Laboratories.

The Major Players Opearting in the Blood Screening Market:

The prominent players in the Blood Screening Market include Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Siemens Healthineers (Germany).

Major Market Development:

  • In June 2016, Grifols and Hologic, Inc. (U.S.) announced the U.S. FDA approval of the Procleix Zika virus blood-screening assay on the Procleix Panther system under the agency’s Investigational New Drug (IND) study protocol. This enhanced the company’s portfolio of blood screening products.
  • In October 2016, Roche announced the FDA approval of the cobas MPX test for use on the cobas 6800 and 8800 Systems. This detects HIV-1, HIV-2, HBV, and HCV in transfused blood products.
  • In July 2015, Roche announced the market availability of the Elecsys HTLV-I/II immunoassay. This diagnostic test detects antibodies against Human T-lymphotropic virus I & II infections in donated blood and routine diagnostic samples.

The ****** Blood Screening Market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to witness the highest CAGR during the forecast period, with the growth in this market centred at China, Japan, and India.

Target Audience for this Report:

  • Blood Screening Instruments and Reagents Manufacturers
  • Blood Screening Software and Services Providers
  • Blood Banks
  • Hospitals
  • Red Cross Societies
  • Regulatory Bodies
  • Research and Consulting Firms
  • Government Bodies

Read More in Detailed (Blood Screening):